Cancer News and Research

Latest Cancer News and Research

Seattle genetics new blood cancer drug Adcetris comes with a hefty price tag

Seattle Genetics Inc's new blood cancer drug Adcetris is will come with a price tag of $100,000 for a course of treatment. The U.S. Food and Drug Administration on Friday gave its nod to Adcetris, the first drug specifically indicated for anaplastic large cell lymphoma (ALCL) and the first one approved for Hodgkin's lymphoma since 1977.

23 Aug 2011

Dogs ‘sniff’ out early lung cancer accurately

According to a new study in the European Respiratory Journal dogs are better at sniffing out the early markers of lung cancer than the latest medical technologies at our disposal.

23 Aug 2011

Hutchinson Center to participate in NCI-funded proteome research consortium

The National Cancer Institute today announced that a team co-led by Fred Hutchinson Cancer Research Center and The Broad Institute in Cambridge, Mass., has been selected to participate in a National Cancer Institute-funded research consortium dedicated to understanding the molecular basis of cancer.

23 Aug 2011

BioLineRx second quarter net loss decreases to NIS 16.4 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the second quarter ending June 30, 2011.

23 Aug 2011

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

Patients suffering from an aggressive brain cancer will benefit from the results of a University of Illinois study that could advance the development of targeted gene therapies and improve prognosis.

23 Aug 2011

Roche Canada grants Vasculitis and Scleroderma Fellowship

Roche Canada announced today its support of a Vasculitis and Scleroderma Fellowship through the Division of Rheumatology at the University of British Columbia (UBC). Dr. Ada Man, a recent graduate of the UBC rheumatology residency program, is the recipient of the one-year Fellowship.

23 Aug 2011

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Molecular Endocrinology journal publishes two studies on estrogen hormones

University of Houston (UH) researchers have their sights set on developing possible treatments for breast and colon cancer.

23 Aug 2011

OICR President announces $12.6M in funding for High Impact Clinical Trials Program

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR), today announced $12.6 million in funding over four years for OICR's High Impact Clinical Trials (HICT) Program.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.

23 Aug 2011

Survival for patients with HCC increases with radioembolization

Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is likely to provide survival benefit across different tumor stages, including patients with advanced liver cancer and with limited treatment options.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

Disturbing images and threatening anti-smoking messages can 'boomerang'

Health communicators have long searched for the most effective ways to convince smokers to quit. Now, University of Missouri researchers have found that using a combination of disturbing images and threatening messages to prevent smoking is not effective and could potentially cause an unexpected reaction.

23 Aug 2011

CTI responds to EMA's Day 120 letter for pixantrone MAA

Cell Therapeutics, Inc. today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in regards to CTI's Marketing Authorization Application for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Aug 2011

DMS receives NIH grant to establish Center of Biomedical Research Excellence

Under an $11-million grant from the National Institutes of Health (NIH), Dartmouth Medical School (DMS) will lead a network of northern New England institutions in recruiting, training, and supporting young quantitative biologists to teach and conduct research into the ways that genes and the environment work together to trigger and prevent disease.

23 Aug 2011

Samaritan Medical Center selects ProVation Order Sets electronic solution

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that Samaritan Medical Center has selected ProVation® Order Sets, powered by UpToDate® Decision Support, as the organization's electronic order set solution.

23 Aug 2011